These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 9873524)
21. Endogenous modulation of excitatory amino acid responsiveness by tachykinin NK1 and NK2 receptors in the rat spinal cord. Chizh BA; Cumberbatch MJ; Birch PJ; Headley PM Br J Pharmacol; 1995 Jul; 115(6):1013-9. PubMed ID: 7582497 [TBL] [Abstract][Full Text] [Related]
22. Neurokinin receptors (NK1, NK2) in the mouse: a pharmacological study. Nsa Allogho S; Nguyen-Le XK; Gobeil F; Pheng LH; Regoli D Can J Physiol Pharmacol; 1997 Jun; 75(6):552-7. PubMed ID: 9276127 [TBL] [Abstract][Full Text] [Related]
23. Receptors mediating tachykinin-evoked depolarisations of neurons in the neonatal rat spinal cord. Fox AJ; Naeem S; Patel IA; Walpole C; Urbán L Acta Biol Hung; 1996; 47(1-4):129-44. PubMed ID: 9123986 [TBL] [Abstract][Full Text] [Related]
24. Tachykinins mediate non-adrenergic, non-cholinergic excitatory neurotransmission to the hamster ileum via NK1 and NK2 receptors. El-Mahmoudy A; Matsuyama H; Khalifa M; Shimizu Y; Takewaki T Life Sci; 2003 Aug; 73(15):1939-51. PubMed ID: 12899919 [TBL] [Abstract][Full Text] [Related]
25. Increased blocking activity of combined tachykinin NK1- and NK2-receptor antagonists on hyperventilation-induced bronchoconstriction in the guinea pig. Corboz MR; Fernandez X; Hey JA Pulm Pharmacol Ther; 2008; 21(1):67-72. PubMed ID: 17239637 [TBL] [Abstract][Full Text] [Related]
26. N-[(R,R)-(E)-1-(4-chloro-benzyl)-3-(2-oxo-azepan-3-ylcarbamoyl)-allyl]-N-methyl-3,5-bis-trifluoromethyl-benzamide: an orally active neurokinin NK1/NK2 antagonist. Gerspacher M; von Sprecher A; Mah R; Anderson GP; Bertrand C; Subramanian N; Hauser K; Ball HA Bioorg Med Chem Lett; 2000 Jul; 10(13):1467-70. PubMed ID: 10888334 [TBL] [Abstract][Full Text] [Related]
27. Tachykinin NK1 and NK2 receptor-mediated control of peristaltic propulsion in the guinea-pig small intestine in vitro. Holzer P; Lippe IT; Heinemann A; Barthó L Neuropharmacology; 1998; 37(1):131-8. PubMed ID: 9680266 [TBL] [Abstract][Full Text] [Related]
28. Spiro-substituted piperidines as neurokinin receptor antagonists. I. Design and synthesis of (+/-)-N-[2-(3,4-dichlorophenyl)-4-(spiro [isobenzofuran-1(3H),4'piperidin]-1'-yl)butyl]-N-methylbenzamide, YM-35375, as a new lead compound for novel neurokinin receptor antagonists. Kubota H; Fujii M; Ikeda K; Takeuchi M; Shibanuma T; Isomura Y Chem Pharm Bull (Tokyo); 1998 Feb; 46(2):351-4. PubMed ID: 9501470 [TBL] [Abstract][Full Text] [Related]
29. Spiro-substituted piperidines as neurokinin receptor antagonists. II. Syntheses and NK2 receptor-antagonistic activities of N-[2-aryl-4-(spiro-substituted piperidin-1'-yl)butyl]carboxamides. Kubota H; Kakefuda A; Nagaoka H; Yamamoto O; Ikeda K; Takeuchi M; Shibanuma T; Isomura Y Chem Pharm Bull (Tokyo); 1998 Feb; 46(2):242-54. PubMed ID: 9501460 [TBL] [Abstract][Full Text] [Related]
30. Effect of scyliorhinin I and synthetic scyliorhinin I derivatives at mammalian tachykinin NK1, NK2 and NK3 receptors. Patacchini R; Quartara L; Rolka K; Zboinska J; Kupryszewski G; Maggi CA Eur J Pharmacol; 1993 Dec; 250(2):311-6. PubMed ID: 7509285 [TBL] [Abstract][Full Text] [Related]
31. Synthesis and in vitro activities of NK-1 antagonists derived from L-tryptophan. Caliendo G; Fiorino F; Grieco P; Perissutti E; Santagada V; Calignano A; Mancuso F; Albrizio S Farmaco; 1997 Oct; 52(10):589-93. PubMed ID: 9507670 [TBL] [Abstract][Full Text] [Related]
32. Effect of tachykinin receptor inhibition in the brain on cardiovascular and behavioral responses to stress. Culman J; Klee S; Ohlendorf C; Unger T J Pharmacol Exp Ther; 1997 Jan; 280(1):238-46. PubMed ID: 8996202 [TBL] [Abstract][Full Text] [Related]
33. The non-peptide tachykinin NK1- and NK2-receptor antagonists SR 140333 and SR 48968 prevent castor-oil induced diarrhea in rats. Croci T; Emonds-Alt X; Le Fur G; Maffrand JP; Manara L Acta Physiol Hung; 1996; 84(3):273-4. PubMed ID: 9219603 [TBL] [Abstract][Full Text] [Related]
34. Affinity, potency, efficacy, and selectivity of neurokinin A analogs at human recombinant NK2 and NK1 receptors. Rupniak NMJ; Perdona E; Griffante C; Cavallini P; Sava A; Ricca DJ; Thor KB; Burgard EC; Corsi M PLoS One; 2018; 13(10):e0205894. PubMed ID: 30359406 [TBL] [Abstract][Full Text] [Related]
36. Evidence that tachykinin NK1 and NK2 receptors mediate non-adrenergic non-cholinergic excitation and contraction in the circular muscle of guinea-pig duodenum. Zagorodnyuk V; Santicioli P; Maggi CA; Giachetti A Br J Pharmacol; 1995 May; 115(2):237-46. PubMed ID: 7545517 [TBL] [Abstract][Full Text] [Related]
37. The induction and potentiation of c-Jun and c-Fos expression in spinal neurons mediated by NK1 and NK2 receptors. Redburn JL; Leah JD Neuropeptides; 1999 Apr; 33(2):115-9. PubMed ID: 10657480 [TBL] [Abstract][Full Text] [Related]
38. Tachykinin-mediated respiratory effects in conscious guinea pigs: modulation by NK1 and NK2 receptor antagonists. Kudlacz EM; Logan DE; Shatzer SA; Farrell AM; Baugh LE Eur J Pharmacol; 1993 Sep; 241(1):17-25. PubMed ID: 7693493 [TBL] [Abstract][Full Text] [Related]